Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov;28(11):1519.
doi: 10.1016/j.cmi.2022.06.013. Epub 2022 Jun 20.

Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM

Timothée Klopfenstein  1 , Vincent Gendrin  2 , Souheil Zayet  2
Affiliations
Comment

Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM

Timothée Klopfenstein et al. Clin Microbiol Infect. 2022 Nov.
No abstract available

Keywords: Anti-interleukin-6 receptor; COVID-19; Randomized clinical trial; Sub-groupe analyses; Tocilizumab.

PubMed Disclaimer

Comment in

Comment on

References

    1. Broman N., Feuth T., Vuorinen T., Valtonen M., Hohenthal U., Löyttyniemi E., et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clin Microbiol Infect. 2022;28:844–851. - PMC - PubMed
    1. Klopfenstein T., Gendrin V., Gerazime A., Conrozier T., Balblanc J.C., Royer P.Y., et al. Systematic review and subgroup meta-analysis of randomized trials to determine tocilizumab’s place in COVID-19 pneumonia. Infect Dis Ther. 2021;10:1195–1213. - PMC - PubMed
    1. Tleyjeh I.M., Kashour Z., Riaz M., Hassett L., Veiga V.C., Kashour T. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Clin Microbiol Infect. 2021;27:1076–1082. - PMC - PubMed
    1. Cozzi-Lepri A., Smith C., Mussini C. Signals were broadly positive for months, but never definitive: the tocilizumab story. Clin Microbiol Infect. 2022;28:371–374. - PMC - PubMed

Substances